APREA THERAPEUTICS INC (APRE) Fundamental Analysis & Valuation

NASDAQ:APRE • US03836J2015

Current stock price

0.819 USD
-0.02 (-2.14%)
At close:
0.8066 USD
-0.01 (-1.51%)
After Hours:

This APRE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. APRE Profitability Analysis

1.1 Basic Checks

  • In the past year APRE has reported negative net income.
  • APRE had a negative operating cash flow in the past year.
  • APRE had negative earnings in each of the past 5 years.
  • In the past 5 years APRE always reported negative operating cash flow.
APRE Yearly Net Income VS EBIT VS OCF VS FCFAPRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • APRE has a Return On Assets of -79.08%. This is in the lower half of the industry: APRE underperforms 69.13% of its industry peers.
  • APRE has a Return On Equity (-95.68%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.08%
ROE -95.68%
ROIC N/A
ROA(3y)-65.4%
ROA(5y)-126.92%
ROE(3y)-78.92%
ROE(5y)-145.8%
ROIC(3y)N/A
ROIC(5y)N/A
APRE Yearly ROA, ROE, ROICAPRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for APRE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APRE Yearly Profit, Operating, Gross MarginsAPRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. APRE Health Analysis

2.1 Basic Checks

  • APRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • APRE has more shares outstanding than it did 1 year ago.
  • APRE has more shares outstanding than it did 5 years ago.
  • APRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APRE Yearly Shares OutstandingAPRE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
APRE Yearly Total Debt VS Total AssetsAPRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -29.97, we must say that APRE is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -29.97, APRE is not doing good in the industry: 89.13% of the companies in the same industry are doing better.
  • APRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.97
ROIC/WACCN/A
WACC9.51%
APRE Yearly LT Debt VS Equity VS FCFAPRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • APRE has a Current Ratio of 5.63. This indicates that APRE is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of APRE (5.63) is comparable to the rest of the industry.
  • A Quick Ratio of 5.63 indicates that APRE has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 5.63, APRE is doing good in the industry, outperforming 60.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.63
Quick Ratio 5.63
APRE Yearly Current Assets VS Current LiabilitesAPRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. APRE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.35% over the past year.
  • The Revenue for APRE has decreased by -80.98% in the past year. This is quite bad
EPS 1Y (TTM)40.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.69%
Revenue 1Y (TTM)-80.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.38%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.78% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 89.65% on average over the next years. This is a very strong growth
EPS Next Y14.71%
EPS Next 2Y28.31%
EPS Next 3Y19.55%
EPS Next 5Y18.78%
Revenue Next Year-78.07%
Revenue Next 2Y-41.42%
Revenue Next 3Y6.26%
Revenue Next 5Y89.65%

3.3 Evolution

APRE Yearly Revenue VS EstimatesAPRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
APRE Yearly EPS VS EstimatesAPRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. APRE Valuation Analysis

4.1 Price/Earnings Ratio

  • APRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APRE Price Earnings VS Forward Price EarningsAPRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APRE Per share dataAPRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • APRE's earnings are expected to grow with 19.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.31%
EPS Next 3Y19.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. APRE Dividend Analysis

5.1 Amount

  • APRE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APRE Fundamentals: All Metrics, Ratios and Statistics

APREA THERAPEUTICS INC

NASDAQ:APRE (4/29/2026, 8:00:01 PM)

After market: 0.8066 -0.01 (-1.51%)

0.819

-0.02 (-2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)03-16
Earnings (Next)05-12
Inst Owners12.45%
Inst Owner Change0%
Ins Owners12.49%
Ins Owner Change1.58%
Market Cap9.38M
Revenue(TTM)285.80K
Net Income(TTM)-12.60M
Analysts84.44
Price Target4.49 (448.23%)
Short Float %1.13%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.28%
Min EPS beat(2)-36.13%
Max EPS beat(2)19.56%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.5%
PT rev (3m)-49.23%
EPS NQ rev (1m)-3.03%
EPS NQ rev (3m)-82.8%
EPS NY rev (1m)29.89%
EPS NY rev (3m)36.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 32.81
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.02
BVpS1.15
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -79.08%
ROE -95.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.4%
ROA(5y)-126.92%
ROE(3y)-78.92%
ROE(5y)-145.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.63
Quick Ratio 5.63
Altman-Z -29.97
F-Score1
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.69%
EPS Next Y14.71%
EPS Next 2Y28.31%
EPS Next 3Y19.55%
EPS Next 5Y18.78%
Revenue 1Y (TTM)-80.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.38%
Revenue Next Year-78.07%
Revenue Next 2Y-41.42%
Revenue Next 3Y6.26%
Revenue Next 5Y89.65%
EBIT growth 1Y7.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.99%
EBIT Next 3Y-10.09%
EBIT Next 5YN/A
FCF growth 1Y4.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.89%
OCF growth 3YN/A
OCF growth 5YN/A

APREA THERAPEUTICS INC / APRE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for APREA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to APRE.


What is the valuation status for APRE stock?

ChartMill assigns a valuation rating of 0 / 10 to APREA THERAPEUTICS INC (APRE). This can be considered as Overvalued.


Can you provide the profitability details for APREA THERAPEUTICS INC?

APREA THERAPEUTICS INC (APRE) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for APRE stock?

The Earnings per Share (EPS) of APREA THERAPEUTICS INC (APRE) is expected to grow by 14.71% in the next year.